{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:01Z","timestamp":1761561601375,"version":"3.41.2"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/igc.0b013e318234fa3a","type":"journal-article","created":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T04:29:15Z","timestamp":1324528155000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Bengt","family":"Sorbe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Graflund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Swahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Boman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Bangsh\u00f6j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Lood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henric","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2010","series-title":"GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CaseBase No. 10","author":"Ferlay","key":"10.1097\/IGC.0b013e318234fa3a_bb0005"},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","article-title":"Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO","volume":"61","author":"Sehouli","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0030","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0035","first-page":"73","article-title":"Docetaxel in the treatment of ovarian cancer","volume":"16","author":"Kavanagh","year":"2002","journal-title":"Oncology."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0040","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/sj.bjc.6601495","article-title":"Docetaxel: an alternative taxane in ovarian cancer","volume":"89","author":"Katsumata","year":"2003","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0045","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","article-title":"Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial","volume":"105","author":"Kushner","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2006.10.006","article-title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel\u2013ANZGOG 02-01","volume":"104","author":"Tinker","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2009.02.018","article-title":"A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers","volume":"113","author":"Gupta","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000224658","article-title":"A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism","volume":"55","author":"Safra","year":"2009","journal-title":"Chemotherapy."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s10147-003-0351-7","article-title":"Weekly docetaxel for patients with platinum\/paclitaxel\/irinotecan-resistant relapsed ovarian cancer: a phase I study","volume":"8","author":"Terauchi","year":"2003","journal-title":"Int J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0080","first-page":"299","article-title":"A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer","volume":"6","author":"Komiyama","year":"2005","journal-title":"Eur J Gynaecol Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0085","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0100","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res."},{"year":"2003","series-title":"Common Terminology Criteria for Adverse Events","author":"National Institutes of Health","key":"10.1097\/IGC.0b013e318234fa3a_bb0105"},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","article-title":"Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors","volume":"28","author":"Penson","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0125","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study","volume":"18","author":"Burger","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0130","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0135","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/cncr.11527","article-title":"Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy","volume":"98","author":"Esmaeli","year":"2003","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e318234fa3a_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0090-8258(03)00322-6","article-title":"A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer","volume":"90","author":"Oishi","year":"2003","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e318234fa3a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:29:22Z","timestamp":1753223362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24089035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1048891X24089035"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e318234fa3a","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e318234fa3a","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2012 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}